Biomarking the estrogen responsiveness of breast cancer
Management of symptoms in breast cancer survivors
Multidisciplinary treatment guidelines across the continuum of care: the NCCN experience
Energy balance, insulin, and breast cancer
Radiation treatment planning for breast cancer: a journey through time
Systems approach to growth factor signaling and to therapeutic intervention in breast cancer
Targeting the HER network in breast cancer: therapeutic successes and failures
Identification of biomarkers of resistance to HER2 targeted therapy using loss of function genetic screens
The Women's Health Initiative randomized trials of menopausal hormone therapy: results and impact on clinical practice
Hormone replacement therapy and breast cancer - a summary of results from other studies
Learning from the brain: cancer stem cells in therapeutic resistance and as molecular targets
High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 15 randomized adjuvant breast cancer trials
Extended follow-up and analysis by age of the US Oncology Adjuvant trial 9735: docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/cyclophosphamide and is well-tolerated in women 65 or older
Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: efficacy analyses determined by molecular subtypes of the disease
Outcome of breast cancer therapies for adjuvant versus advanced disease: how much do they differ? Critical comments towards the present process of randomized trials as a pre-requisite for adjuvant therapy guidelines
Long-term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node negative breast cancer
dHER2 cancer immunotherapeutic: clinical response in breast cancer patients is associated with an induction of functional antibodies and the generation of specific T cells
Fulvestrant 500 mg vs 250 mg: first results from NEWEST, a randomized, phase II neoadjuvant trial in postmenopausal women with locally advanced, estrogen receptor-positive breast cancer
Anti-estrogens promote an invasive phenotype in intercellular adhesion deficient breast cancer cells
The VEGF-R inhibitor PTK787/ZK222584 (PTK/ZK) also inhibits aromatase: preclinical studies of PTK/ZK in combination with endocrine therapy
Bone mineral density (BMD) at 5 years after diagnosis in premenopausal patients with endocrine-responsive breast cancer, after 3 years of adjuvant endocrine treatment with goserelin and tamoxifen or anastrozole or both treatments in combination with zoledronic acid - new results from ABCSG-12
The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 36-month follow-up
Effect of anastrozole on bone mineral density after one year of treatment: results from bone sub-study of the International Breast Cancer Intervention Study (IBIS-II)
Risk stratification based on the CYP2D6 tamoxifen metabolizing gene within the Italian tamoxifen prevention trial
Genomic approaches to breast cancer subset identification and treatment
Genome-wide analysis of DNA copy number alterations in conjunction with gene expression profiling identifies DNA amplification loci that predict distant recurrence in lymph node-negative (LNN) primary breast cancer patients
Gene expression profiles of ER+/PR− breast cancer are associated with genomic instability and Akt/mTOR signaling, and predict poor patient outcome better than clinically assigned PR status
Expression of alphavbeta6 supersedes Her2 and triple-negative/basal classification of breast cancer and defines novel subgroups with poor survival: implications for breast cancer classification and treatment
A stroma-related gene signature predicts resistance to epirubicin-containing neoadjuvant chemotherapy in breast cancer
The clinical significance of polysomy 17 in the HER2+ N9831 intergroup adjuvant trastuzumab trial
Multidrug resistance and breast cancer: a meta-analysis of MDR1 and its clinical significance
ATAC: 100 month median follow-up (FU) shows continued superior efficacy and no excess fracture risk for anastrozole (A) compared with tamoxifen (T) after treatment completion
Mid-term efficacy of a breast cancer screening program for women with a familial or genetic susceptibility: update of the Dutch MRI screening study (MRISC)
Detection of enhancing lesions on contrast-enhanced MRI of the breast using real-time virtual sonography: fusion of MRI and sonography data
MRI for diagnosing pure ductal carcinoma in-situ
Noninvasive monitoring of neoadjuvant chemotherapy using optical tomography with ultrasound localization: initial experience
Tomosynthesis for the detection of breast cancer in a clinical setting
Is completion axillary dissection always required after a positive sentinel node biopsy? NSABP B-32
The impact of micrometastases in the sentinel nodes of patients with invasive breast cancer
High sensitivity of a molecular assay for breast metastases in sentinel lymph nodes that are difficult to detect by frozen section
Increased sentinel lymph node lymphangiogenesis predicts non-sentinel axillary lymph node involvement in breast cancer patients with a positive sentinel node
The influence of a very high vegetable-fruit-fiber, low-fat diet on prognosis following treatment for breast cancer: results from the Women's Healthy Eating and Living (WHEL) randomized trial
Outcome prediction for clinical stage II and III ER+ breast cancer based on treatment response, pathological stage, tumor grade, Ki67 proliferation index, and estrogen receptor status after neoadjuvant endocrine therapy
Prognostic utility of the 21-gene assay compared with Adjuvant! in hormone receptor (HR) positive operable breast cancer with 0-3 positive axillary nodes treated with adjuvant chemohormonal therapy (CHT): an analysis of intergroup trial E2197
Value of centrally-assessed Ki-67 labeling index as a marker of prognosis and predictor of response to adjuvant endocrine therapy in the BIG 1-98 trial of postmenopausal women with estrogen receptor-positive breast cancer
Erythropoietin receptor expression in breast cancer and correlation to tamoxifen response
Inflammatory breast cancer pathogenesis is mediated in significant part by translation initiation factor eIF4G amplification and unorthodox protein synthesis
Disease-free survival according to local immunohistochemistry for HER2 and central fluorescence in situ hydridization for patients treated with adjuvant chemotherapy with and without trastuzumab in the HERA (BIG 01-01) trial
3-year follow-up of trastuzumab following adjuvant chemotherapy in node positive HER2-positive breast cancer patients: results of the PACS-04 trial
Safety of pertuzumab plus trastuzumab in a phase II trial of patients with HER2-overexpressing metastatic breast cancer which had progressed during trastuzumab therapy
Combination of nab-paclitaxel and bevacizumab eradicates well-established tumors as well as lymphatic and pulmonary metastases in a MDA-MB-231 model of a highly metastatic human breast cancer
ErbB-2 inhibition activates notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor: opportunity for a novel therapeutic combination
Parity regulates activation of p53 in human breast tissue
Cytochrome P450 2D6 activity predicts adherence to tamoxifen therapy
Preliminary results of the UK Taxotere as Adjuvant Chemotherapy (TACT) Trial
Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/cyclophosphamide → docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/AGO intergroup-study "GeparQuattro"
Characterizing the biology and response of locally advanced breast cancer in women undergoing neoadjuvant therapy: preliminary results from the I-SPY trial
Elucidating the stem and progenitor cell hierarchy in breast development and cancer - an essential role for GATA-3
Decrease in tumorigenic breast cancer stem cells in primary breast cancers with neoadjuvant lapatinib
Serial detection and characterization of circulating tumor cells in an animal model
A new system for enrichment and detection of circulating tumor cells in the peripheral blood of patients with metastatic breast cancer
MagSweeper: an automated system for high efficiency and specificity capture of live circulating tumor cells
Circulating tumor cells as a reliable assessment of treatment efficacy in metastatic breast cancer
Disseminated tumor cells correlate with estrogen receptor positivity in operable breast cancer patients
Features of patients (pts) with metastatic breast cancer (mBC) and a circulating tumor cell count (CTCc) of 0
Bone marrow micrometastasis and circulating tumor cells are respectively strong prognostic factors in early and metastatic breast cancer, a comparative study on 759 patients
Prognostic value of the detection of circulating tumor cells using a multimarker RT-PCR (CK19, mammaglobin A, HER2/neu) in early breast cancer
Circulating CK-19 mRNA (+) cells in patients with stage I and II breast cancer after the completion of adjuvant chemotherapy: evaluation of their prognostic relevance
Circulating epithelial tumor cells a new tool for therapy monitoring in breast cancer: a more than tenfold increase in numbers during systemic therapy is highly predictive of relapse
A unique model of estrogen receptor (ER) α-positive breast cancer metastasis
Primary tumor heterogeneity and sentinel lymph node metastases: understanding molecular processes of breast cancer metastasis
Identification of genetic predisposition to development of lymph node metastasis in breast cancer patients
Identification of new candidate breast cancer metastasis genes
ALDH1 positive stem cells in inflammatory breast cancer mediate metastasis and are associated with a poor clinical outcome
Programmed cell death 4, a novel inhibitor of breast cancer invasion
TROP2 is a novel, major determinant in breast cancer growth and metastatization
Osteoblasts and their progenitors stimulate breast cancer cell migration through chemokine secretion
Significance of PELP1/MNAR-mediated ER-nongenotropic actions in cytoskeleton signaling
Lapatinib prevents the metastatic colonization of EGFR+ and Her-2+ breast cancer cells in the brain
Optimal dose and schedule of a HER2/neu peptide (E75) vaccine in disease-free breast cancer patients: results from two phase I/II clinical trials
Clinical results of a phase I trial of a HER2/neu-derived peptide (GP2) vaccine in disease-free, node-negative breast cancer patients
Immunotherapy against metastatic breast cancer with a twist
10 years follow up of pilot phase III immunotherapy study in early stage breast cancer patients using oxidized mannan-MUC1
Circulating immature myeloid cells in breast cancer patients correlate with clinical cancer stage and cyclophosphamide treatment: implications for cancer immunotherapy
Targeting of the chemokine receptor CXCR4 in acquired trastuzumab resistance
TBCRC 001: EGFR inhibition with cetuximab in metastatic triple negative (basal-like) breast cancer
Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer
Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer
A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with advanced HER2+ breast cancer
Patterns of estrogen receptor alpha (ER) protein expression and ESR1 gene amplification in primary and metastatic breast cancer
Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer
Relationship between ESR1 copy number and ER expression in the DBCG 89D trial
Gene copy number variability of oestrogen receptor-α in breast cancer
Serine118 phosphorylation of estrogen receptor: correlation with kinase pathways and evolution after preoperative endocrine therapy
Induction of a novel estrogen receptor (ERα) phospho-serine (S154) in human breast cancer cells identified by mass spectrometry
Withdrawn by author
Mitogen activated protein kinase (MAPK) regulation of estrogen receptor (ER) α and tamoxifen resistance
Single nucleotide polymorphism 3814 C>T (P1272S) in steroid receptor coactivator-1 alters its coactivation activity
The ZO-FAST trial: zoledronic acid effectively inhibits aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 24 month BMD results
The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: 12-month analysis
The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women on SERMS versus aromatase inhibitors: a 2 year trial
Practical guidance for the prevention of aromatase inhibitor-associated bone loss in women with breast cancer
Effect of zoledronic acid on bone loss in women undergoing chemotherapy for breast cancer
Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early stage breast cancer
Differential effects of doxorubicin and zoledronic acid on intra-osseous vs extra-osseous breast tumour growth in vivo
Survival in breast cancer patients with bone metastases and reductions in markers of bone resorption during zoledronic acid treatment
Effects of zoledronic acid on wnt inhibition by dickkopf1 and frizzled-related protein in patients with bone metastases
Zoledronic acid as adjuvant therapy for women with early stage breast cancer and occult tumor cells in bone marrow
Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer
Effect of magnetic resonance imaging on the clinical management of women with newly diagnosed breast cancer
Deconvolution-based dynamic contrast enhanced MRI of breast cancer: correlation of tumor blood flow with pathologic and molecular markers
A new approach to studying the progression of mammary gland carcinoma in mice: high resolution MRI of early cancer and DCIS
Magnetic resonance imaging in predicting pathologic residual disease after primary induction chemotherapy
How does ER/PR and Her2/Neu status affect the MR characteristics of invasive ductal carcinoma?
Breast density assessment using magnetic tesonance imaging and diffuse optical spectroscopy
MR imaging of tumor response in breast cancer patients following neoadjuvant chemotherapy: correlated with pathological findings
The utility of MRI in preoperative planning for breast-conserving therapy
Does MRI improve chances of obtaining negative surgical margins after localized excision? A retrospective study
The role of breast MRI in the preoperative evaluation of patients with newly diagnosed breast cancer
Comparative accuracy of MRI and ultrasound for predicting breast cancer extent after neoadjuvant chemotherapy
Accuracy of preoperative evaluation of the axilla with MRI in breast cancer
Model selection for analysis of dynamic contrast enhanced MRI (DCE-MRI) data
Are the MRI characteristics of malignant breast lesions different for African American women?
Pushing the limits: very high spatial resolution spectroscopic MR imaging of human breast
The effect of computer-aided detection on the interpretation of screening mammograms at Intermountain Healthcare facilities
Telemammography in a rural community
Mammography screening and other preventive care among African American and native American women with access to health care
Initial clinical evaluation of laser optoacoustic imaging system for diagnostic imaging of breast cancer
Sonobreast: a novel predictive model for the risk of malignancy in solid breast nodules with echographic expression
High resolution positron emission mammography in breast cancer management
A comparison study between multidetector-row CT and histopathological findings in terms of the extension diagnosis of breast cancer
Correlation of Ki67 expression with FDG-PET positivity in triple negative breast cancer
Breast optical tomography: sensitivities and specificities for the detection of cancer
Mammographic features of triple-negative versus HER2+ and ER+ breast cancers
Effects of the steroidal aromatase inhibitor exemestane on mammographic breast density and other end-organ functions
Influence of bilateral breast magnetic resonance imaging in treatment planning for patients with stage I/II breast cancer
Follow-up rather than excision for benign papillary lesions of the breast
Using three-parameter empirical mathematical model to analyze breast DCEMRI data; comparison with conventional BI-RADS classification
A double-blind randomized controlled trial of paracetamol as a pre-medication for mammography
Why women with breast cancer do not return for surveillance mammography
Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy
Breast specific gamma imaging and managment of breast cancer
The missing exam in clinical breast exam
Comparing performance measures in opportunistic and organized screening mammography for early breast cancer detection
Cost-effectiveness of breast cancer (BC) screening with contrast enhanced magnetic resonance imaging (MRI) as an adjunct to x-ray mammography (XM) in high-risk women
High incidence of brain metastases found in patients with HER2 positive metastatic breast cancer. Should these patients be followed by regular MR scans?
Concordance of contralateral breast cancer for steroid receptor and tumour characteristics
Breast cancer in the elderly: benefits of screening mammography in the diagnosis
Utility of echocardiographic screening for late-onset cardiomyopathy in breast cancer survivors treated with cardiotoxic chemotherapy
Does HER-2 status influence locoregional failure rates after mastectomy in patients with pT1-3pN0 early stage breast cancer?
Elevated JAG1 mRNA expression, associated with the basal phenotype, is a poor-prognosis indicator in lymph node-negative breast cancer
Recurrence score by oncotype DX evaluated on the primary breast tumor predicts the 2-year survival after first relapse
Intracystic papillary carcinoma: a review of 917 cases
Short term prognostic index for breast cancer: NPI or Lpi
The microstaging of sentinel lymph node biopsies is not associated with disease-free survival in breast cancer
Meta-analysis of gene-expression profiles in breast cancer: towards a unified understanding of breast cancer sub-typing and prognosis signatures
The presence of a fibrotic focus and expansive growth pattern in breast tumors is associated with gene expression profiles of aggressive tumor biology
An inflammatory breast carcinoma signature is associated with reduced relapse free survival in patients with non-inflammatory breast cancer
Plasma and serum levels of tissue inhibitor of metalloproteinases-1 are associated with prognosis in node-negative breast cancer - a prospective study
Non-proportional breast cancer mortality patterns according to expression of the HER2 protein, using the residual tissue repository of the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program
Reassigned to 3113
Patterns of metastatic spread in triple negative breast cancer
E-cadherin levels may predeict outcome in inflammatory breast cancer (IBC)
Impact of hormone replacement therapy on breast cancer: Women's Healthy Eating and Living (WHEL) study experience
Survival outcomes in pregnancy-associated breast cancer
Clinicopathological and prognostic relevance of uptake level revealed by 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer
Prognostic differences of WHO-assessed mitotic activity index (MAI) and mitotic impression by quick scanning in invasive ductal breast cancer patients under 55 years of age
Complementary and alternative therapies among long-term breast cancer survivors
The prognostic significance of human epidermal growth factor receptor-2 over-expression for the development of local recurrence after newly diagnosed breast cancer
Do grade I breast cancers require follow-up after breast conserving treatment?
Prognostic factors for BRCA1/2-associated familial breast cancer from Russian population
Restratification of the Nottingham prognostic index using carcinoembroinic antigen cell adhesion molecule 6
The Amsterdam 70-gene signature predicts outcome in breast cancer patients with 1-3 positive axillary lymph nodes
Quantitative justification of the change from 10% to 30% for HER-2 scoring in the ASCO-CAP guidelines: tumor heterogeneity in breast cancer and its prognostic and predictive implications
HER2 status adds prognostic, but not tamoxifen treatment predictive, information in hormone receptor positive premenopausal primary breast cancer
Prospective prognostic value of proliferation in small, low-grade, lymph-node negative breast cancers
Identification of IGFBP4 as a marker of tamoxifen failure in primary breast cancer
Genomic copy number alterations as predictive markers of systemic recurrence in breast cancer
Prognostic value of the shed antigen of HER-2/neu in premenopausal breast cancer patients in the TABLE-study
Down regulation of EFEMP1 is associated with unfavourable prognosis in sporadic breast cancer patients
Cell cycle proteins add independent prognostic information to Nottingham Prognostic Index (NPI)
The prognostic significance of androgen receptor expression in breast cancer
Comparative analysis of uPA/PAI-1 in core biopsies versus surgical breast cancer samples
Risk of dementia in older breast cancer survivors: a population-based cohort study of the effect of chemotherapy
Final results of the AGO breast cancer study group MAMMA-3 trial: first-line capecitabine + paclitaxel vs epirubicin + paclitaxel for high-risk metastatic breast cancer
Combined trastuzumab (HER)/docetaxel (TAX) versus sequential trastuzumab followed by docetaxel at progression as first line chemotherapy for Her2-positive metastatic breast cancer: preliminary results (multicenter BOOG-study; 2002-02)
Phase III study of gemcitabine plus docetaxel versus capecitabine plus docetaxel for anthracycline-pretreated metastatic breast cancer patients: survival results
Analysis of chemotherapy-induced amenorrhea by three different chemotherapy regimens in premenopausal women with early breast cancer
A descriptive study of pharmacokinetic alterations of epirubicin as a function of body size
A multicenter, randomized, double-blind, parallel-group phase II study of gefitinib (IRESSA) or placebo in combination with docetaxel, as first-line treatment in patients with metastatic breast cancer
Vinflunine in combination with trastuzumab: an active combination in the treatment of HER2 positive metastatic breast cancer
A phase III study on the efficacy and safety of docetaxel, every three weeks or as a weekly regimen in patients with metastatic breast cancer
Benchmarking quality oncology care in the community setting
Age and prognosis - how did adjuvant therapies influence the real prognosis?
Dexamethasone, metoclopropamide and omperazole combination is simple, safe and effective for delayed nausea and vomiting control in adjuvant chemotheray for early breast cancer
N0332 phase II trial of weekly irinotecan and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group trial
Reduced incidence of febrile neutropenia and related complications in elderly breast cancer patients receiving chemotherapy with pegfilgrastim primary prophylaxis versus current practice neutropenia management - results from an integrated analysis
Pegfilgrastim promotes neutrophil recovery in elderly breast cancer patients following anthracycline-containing chemotherapy
Pre-treatment differential white blood cell counts can be used to identify patients who are at increased risk of severe myelosuppression following adjuvant chemotherapy
Quality of life in the Intergroup Exemestane Study (IES) 5 years post-randomisation
Prospective multi-center study of the impact of the 21-gene recurrence score assay on patient satisfaction, anxiety and decisional conflict for adjuvant breast cancer treatment selection
Predictors of weight gain in patients with early stage breast cancer
Memory loss after adjuvant chemotherapy for breast cancer: a preliminary analysis of mediating variables utilizing cross-sectional correlations and multilevel longitudinal analysis
Research on optimal recovery practices in breast cancer: the RESTORE trial
Breaking bad news: experiences receiving breast cancer diagnosis in a specialty breast center versus community practice
Appraisals, coping and distress among couples dealing with breast cancer
The psychosocial issues for women diagnosed with breast cancer who have a concurrent pregnancy or want the option of a subsequent pregnancy
Prevalence of cognitive complaints is not higher in postmenopausal breast cancer patients before adjuvant hormonal therapy compared to healthy controls
Unexpected effects of reassurance in women with low-risk breast cancer
Breast reconstruction in a university-based public hospital
Anti-tumor activity of motesanib diphosphate alone and in combination with docetaxel or tamoxifen in xenograft models of human breast carcinoma
Non-invasive in vivo subcellular multicolor imaging of the tumor microenvironment and drug response in real time
Anti-angiogenic potential of coenzyme Q10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy
Molecular imaging in the mouse model of breast cancer based on optical illumination and ultrasonic detection
Variation of circulating angiogenic factor level and its potential value during chemotherapy in patients with metastatic breast cancer
Association of genetic polymorphisms of VEGF and VEGFR-2 with outcome in E2100
A novel assay to assess the antiangiogenic potential of cytotoxic drugs in human breast cancer
Comparing serum levels of vascular endothelial growth factor in premenopausic women with breast cancer according to menstrual cycle phase
Nuclear FoxO3a expression is associated with lymph node negative, ER+ invasive ductal carcinomas
Labeling pattern of breast cancer stem phenotype in invasive breast carcinomas: an immunohistochemical analysis
Differential proteomic profiles observed in FFPE breast tissue specimens of several pathologic states
Insulin-like growth factor I activates gene transcription programs strongly associated with ER - breast cancer and poor patient prognosis
HER-1 overexpression is found only in oestrogen receptor negative breast cancer and is rarely associated with HER-1 gene amplification
Effectiveness of RAD001 (everolimus) in combination with endocrine therapy varies with cell phenotype
Combination therapy with tetramethoxystilbene and phosphatidylinositol 3-kinase inhibitor is effective for killing hormone-resistant breast cancer
Inhibition of breast cancer growth with the combination of lapatinib and an ADAM protease inhibitor
uPAR gene amplification in breast cancer tissue: a rare event
Targeting of mTOR is associated with decreased VEGF expression and secretion in cancer cells
Elevated serum TIMP-1/HER-2 predicts decreased response and survival in metastatic breast cancer
Plasminogen activator inhibitor-1 and tissue inhibitor of metalloproteinases-1 are additive in predicting response to chemotherapy in metastatic breast cancer
17β-hydroxysteroid dehydrogenase type 1 is a predictive factor in premenopausal hormone receptor positive breast cancer treated with tamoxifen
A high ratio of 17HSD1/17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer
TOP2A gene amplification and response to adriamycin based therapy
Double staining chromogenic in situ hybridization is a useful alternative to fluorescent in situ hybridization: first comparative study of HER2 and TOP2A gene amplification in breast cancer
Quantitative measurements of HER2 expression and HER2: HER2 dimerization identify subgroups of HER2 positive metastatic breast cancer patients with different probabilities of response to trastuzumab treatment
Inter-observer interpretative reproducibility of HER2 genotyping of a consecutive series of primary breast carcinomas by Silver In Situ Hybridization (SISH)
HER2 tumors are heterogeneous, clinically, molecularly, and in response to preoperative trastuzumab: pathway analysis of gene expression profiles from three breast cancer datasets
Comparison of ERBB2 evaluation by immuno-histochemistry and a quantitative RT-PCR method in primary breast cancers
Development of novel proximity-based immunoassays for the detection of HER heterodimerization in breast cancer cell line lysates and formalin-fixed, paraffin-embedded tissue
Characterization of a novel proximity immunoassay for the quantitative determination of HER2 protein expression and HER2 homodimerization in formalin-fixed, paraffin-embedded breast cancer tissue
HER2 and SPARC status in tumors play an important role in the relative effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel
HER2 immunohistochemistry: comparison of image analysis based interpretation of CB11 and 4B5 clones using reference fluorescence in-situ hybridization
Expression of the microtubule-associated protein, tau, predicts improved survival, but not response, to a combination of docetaxel and vinorelbine in HER-2 negative metastatic breast cancer
Microtubule-associated protein tau is a marker of pathological complete response in Her-2/neu positive neoadjuvant treated breast cancer patients
Cyclin-dependent kinase 2 to 1 specific activity ratio predicts response to epirubicin and paclitaxel in human breast cancer
High pretreatment cyclin E levels may define a higher risk subset of basal-like breast cancers: in depth immunohistochemical analysis and clinical outcome of neoadjuvantly treated basal-like breast cancers
Adding the estimation of cyclin D1 gene amplification to the standard panel of predictors in breast carcinoma can significantly improve identification of tumors resistant to tamoxifen
Single agent in vitro drug sensitivity of molecular breast cancer subtypes defined by gene expression analysis
Tumour volume analysis. A better way than RECIST?
Association of an extracellular matrix gene cluster with breast cancer prognosis and response to tamoxifen
Increased b1 integrin expression is a predictor of trastuzumab resistance in HER-2 overexpressing metastatic breast cancer patients
Preliminary results from I-SPY trial: tumor patterns on pre-treatment MRI predict breast conservation therapy eligibility
Molecular markers as predictors of breast cancer response to adjuvant epirubicin-CMF chemotherapy in the BR9601 trial
Identification of molecular predictors of response of advanced breast cancer patients to aromatase inhibition
Diet, lifestyle, and BRCA-related breast cancer risk among French-Canadian
Milk products are a source of dietary progesterone
Cardioprotective effects of oral dietary glutamine in tumor-bearing rats treated with doxorubicin
Effects of Korean red ginseng on the concentration of blood estrogen, leptin and urinary excretion of estrogen metabolites in postmenopausal women
Breast cancer survivors who use selected herbal supplements have lower circulating estradiol and free estradiol: the Health, Eating, Activity and Lifestyle study
Toward individualized risk prediction: the clinical benefit of risk reduction mastectomy and oophorectomy in BRCA carriers with breast cancer
A BRCA1 or BRCA2 mutation and young age predict fast breast cancer growth. Implications for screening?
Breast carcinoma in situ and the prevalence of BRCA1 and BRCA2 mutations in a large commercial database
Lifetime risk for breast and ovarian cancer in postmenopausal BRCA carriers: cause for concern?
BRCA1- and BRCA2-associated breast cancer is more sensitive to standard chemotherapy for metastatic disease in comparison with sporadic breast cancer
BRCA mutation in Chinese population: preliminary results from the Hong Kong hereditary and high risk breast cancer programme
The CHEK2*1100delC variant: present in the west of Ireland breast cancer population
Addressing the needs of men in BRCA1/2 families
Identification of a recurring BRCA1 mutation in Bahamian women with breast cancer
BRCA1 and BRCA2 mutation carrier predictions using the BRCAPRO model in clinic-based minority families
Outcome in BRCA2 mutation carriers is superior to that of high-risk women with sporadic breast cancer
BRCA mutations among women with bilateral breast cancer: mutation carrier rate and sensitivity of the BRCAPRO model based on age at first diagnosis
Large genomic alterations in BRCA1 in young women with breast cancer participating in the breast cancer family registry
Clinical characteristics and choices regarding prophylactic surgery in BRCA mutation carriers
Cancer-predictive methylation patterns in hereditary breast cancer
BRCA testing in underserved women: 5 years of follow-up
Prophylactic surgeries among BRCA1/2 mutation carriers in the Netherlands
Breast cancer outcomes in an ethnically diverse clinic-based cohort of high-risk individuals
Different rate of BRCA1/BRCA2 predisposing mutations according to family history and clinical criteria of breast/ovarian cancer risk
Endogenous sex hormones and family history of breast cancer in Chinese women
Systemic treatment of transforming growth factor-beta (TGFβ) antagonists inhibited osteolytic bone metastasis induced by human breast cancer cells
Bone-derived IGF-1 enhances bone pain through activation of acid-sensing nociceptors in bone metastases of breast cancer
Patients' disease and treatment parameters significantly affect survival in metastatic breast cancer
Natural history of skeletal complications in patients receiving chemotherapy for breast cancer metastatic to bone
Application of preventive measures minimizes the occurrence of the osteonecrosis of the jaw (ONJ) in solid tumors patients (pts) with bone metastases treated with bisphosphonates (BPs): a single Institution series
Bone pain effectiveness and renal safety of ibandronate in breast cancer patients - are results of controlled clinical trials consistent with daily clinical practice? Interim analysis of a non-interventional post marketing surveillance trial in Germany
Cost-effectiveness of late extended adjuvant letrozole following a prolonged therapy break from tamoxifen - MA-17 post-unblinding analysis
Comparison of cost of distant disease-free year gained of aromatase inhibitors letrozole, anastrozole or exemestane versus tamoxifen for early breast cancer in hormone receptor-positive postmenopausal women: Canadian perspective
Surgical follow-up for low to average risk breast cancer patients: too much too soon?
A retrospective analysis of the impact of oncotype DX low recurrence score results on treatment decisions in a single academic breast cancer center
A cohort study of the total health care costs for modern treatment of disseminated breast cancer
Halved pegfilgrastim doses in adjuvant breast cancer patients associated with similar efficacy but reduced toxicity
Cost-effectiveness analysis of trastuzumab therapy in patients with early HER-2 positive breast cancer in Brazil
Cost comparison of capecitabine in the treatment of patients with breast cancer: an analysis from a claims database
Phase II double-blind randomized trial of daily oral RAD001 (everolimus) plus letrozole (LET) or placebo (P) plus LET as neoadjuvant therapy for ER+ breast cancer
Randomized Phase II study of gefitinib (IRESSA) or placebo in combination with tamoxifen in patients with hormone receptor positive metastatic breast cancer
Withdrawn by author
Hot flushes and the risk of recurrence - retrospective, exploratory results from the ATAC trial
Withdrawn by author
Risk factors for joint symptoms in the ATAC trial
Comparison of joint problems as reported by patients in a randomised adjuvant trial of anastrozole and letrozole
The effect of anastrozole on bone mineral density: updated results from the bone subprotocol of the ATAC trial
A randomised study of the effects of letrozole and anastrozole on bone turnover
Increased efficacy and combination therapy: targeted letrozole/estrogen receptor-β specific ligand nanoparticles homing to mammary tumors in HER-2/aromatase double transgenic mice
Molecular characterization of aromatase inhibitor resistance: a genome-based approach
Therapeutic strategies using aromatase inhibitors and tamoxifen in a post-menopausal breast cancer model
Endometrial status in the Intergroup Exemestane Study (IES) up to 2 years post-treatment
Adjuvant aromatase inhibitors in early breast cancer - toxicity and adherence. Important observations in clinical practice
Increased prevalence of retinal hemorrhages among anastrozole users
New treatment strategies using aromatase inhibitors: a preclinical study
A placebo-controlled trial examining the effects of letrozole on mammographic breast density and bone and lipid metabolism
Survival analysis of first-line tamoxifen versus aromatase inhibitors for estrogen-positive metastatic breast cancer in postmenopausal women - a BC perspective
Impact of CYP2A6 genotype on pharmacokinetics, safety and efficacy of letrozole treatment in Japanese postmenopausal women with metastatic breast cancer
Bone health and anastrozole adverse events in Japan
The effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: preliminary results of N-SAS (national surgical adjuvant study) BC04, the TEAM Japan sub-study
LET-LOB: preoperative letrozole plus lapatinib or placebo in hormone-receptor positive HER2 negative operable breast cancer. Preliminary report of activity and cardiac tolerability
Health-related quality of life and psychological distress in Japanese patients with breast cancer treated with tamoxifen, exemestane or anastrozole for adjuvant therapy: a phase III randomized study of National Surgical Adjuvant Study of Breast Cancer (N-SAS BC) 04
The lipid metabolism of SERMs and AI with primary breast cancer: combined results of Multi 01 and 02 trial
Estrogen deprivation is crucial for the antitumor effect of fulvestrant and adding the HER inhibitor gefitinib delays acquired resistance in a xenograft model of ER-positive breast cancer
Fulvestrant vs exemestane following non-steroidal aromatase inhibitor failure: first overall survival data from the EFECT trial
Pharmacokinetic profile of the fulvestrant (Fasolodex™) loading-dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer
Fulvestrant does not stimulate endometrial growth in postmenopausal breast cancer patients
Fulvestrant in pretreated postmenopausal patients with metastatic breast cancer: analysis from the French multicentre compassionate use programme
Plasma immunoreactive estradiol is increased during therapy with fulvestrant in menopausal breast cancer patients
HDAC inhibitors sensitize ER negative breast cancer cells to AIs
Phase II trial of the HDAC inhibitor, vorinostat, in combination with tamoxifen for patients with advanced breast cancer who have failed prior anti-hormonal therapy
Tamoxifen resistance and tumor initiation mediated by Dicer overexpression in breast cancer progenitor cells - role of BCRP
Co-prescription rates of tamoxifen and CYP2D6 inhibitors: are we compromising breast cancer outcome?
Association of chemotherapy and estrogen receptor genotype with change in bone mineral density after one year of tamoxifen therapy
Late tamoxifen treatment in patients previously operated for breast cancer without postoperative tamoxifen: interim analysis
Randomized phase III trial of exemestane or tamoxifen in first-line hormonal treatment of postmenopausal women with metastatic breast cancer
Tamoxifen withdrawal syndrome
Downregulated expression of SIAH2, an ubiquitin E3 ligase, is associated with endocrine therapy failure
PET FES measures uterine and tumor in vivo pharmacodynamics of endocrine therapy
Adjuvant hormonal therapy choice in women with early stage breast cancer
A systematic review of the role of adjuvant ovarian ablation in the treatment of women with early stage breast cancer
Trilostane (modrenal) as a hormonal treatment for post-menopausal women with breast cancer
Characterization of anti-MUC1 immune response in patients with in situ, early and locally-advanced breast cancer
Relation of intratumoral B-cells and response to neoadjuvant chemotherapy
Decreased accumulation of CD163-positive macrophages is associated with nodal metastases in patients with breast cancer
Immunological status of micrometastasis-positive sentinel nodes in breast cancer patients
Clinicopathological significance of regulatory T cells in breast cancer
Alternatively activated macrophages promote the invasiveness of breast cancer cells
Mechanism of action of herceptin killing of HER-2+ breast cancer cells under "in vitro" and "in vivo" conditions
Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I clinical trial
Lentivirus-mediated oncogene delivery to initiate tumors in mouse mammary epithelial cells
FGFR1 amplification is a breast cancer treatment target and is associated with endocrine therapy resistance
Identification of proline-, glutamic acid-, leucine, rich protein (PELP1) as a novel CDK4 substrate and characterizing its role in breast cancer cell proliferation
The regulation of LKB1 by hormones and its implications for post-menopausal breast cancer
Androgen receptor CAG repeats, haplotypes, non-random X chromosome inactivation, and LOH at Xq25 in relation to breast cancer risk
Is intraoperative cytology of sentinel nodes useful and predictive for non-sentinel axillary nodes? NSABP B-32
First clinical results on the potential of intraoperative imaging for sentinel lymph node biopsy in breast cancer
Optical biopsy scanner utilising elastic scattering spectroscopy for rapid intra-operative diagnosis of sentinel node metastases in breast cancer
Sentinel lymph node biopsy for advanced breast cancer after neoadjuvant chemotherapy: results of the French multicenter prospective trial GANEA
The basal breast cancer molecular subtype predicts for a lower incidence of axillary lymph node involvement in primary breast cancer
Axillary staging is more accurate today than ever before: no increase in the false negative rate with wide-spread adoption of sentinel node technique
Rapid detection of lymph node metastasis in breast cancer patients by "One-step Nucleic Acid Amplification (OSNA)": results from a multi-institutional clinical study
Clinical significance of occult axillary lymph node metastases in breast cancer patients without adjuvant systemic therapy: a long-term retrospective study
Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor-2 (HER2) overexpression in breast cancer
Peripheral blood microarray data may aid in predicting lymph node status of breast cancer patients
Magnetic nanoparticles for detecting cancer spread
Intra-operative assessment of sentinel lymph node using real time quantitative PCR versus delayed assessment of sentinel lymph node: a cost-effectiveness model
Discriminating between sentinel node micrometastases and sub micrometastases is not contributive to omit axillary lymph node dissection
Scoring system to predict non-sentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: comparison with other scoring systems and nomogram
Detailed pathologic evaluation of non-sentinel axillary lymph nodes following identification of sentinel lymph node metastases by cytokeratin immunohistochemistry and/or permanent section H&E levels
'One Step Nucleic Acid Amplification' for rapid molecular analysis of breast cancer lymph nodes: the way towards one stop sentinel node surgery?
Rapid detection of sentinel lymph node metastasis in breast cancer by OSNA assay
Preoperative axillary ultrasound and fine needle aspiration cytology of the axillary nodes in the diagnosis of axillary nodal involvement in breast cancer
Metastatic pattern of axillary lymph nodes after sentinel lymph node on 3D-CT lymphography
The necessity of two gene markers for accurate detection of lymph node micrometastasis using an investigational real time RT-PCR assay confirmed by 0.2 mm interval frozen section analysis in breast cancer
Navigation surgery using a dye and fluorescence for detecting sentinel lymph nodes in breast cancer
Real time reverse transcriptase-polymerase chain reaction assay as an adjuvant tool in evaluation of breast cancer sentinel lymph nodes
Sentinel node excision after neoadjuvant chemotherapy - a multicentric analysis
Clinicopathologic factors associated with microinvasion in ductal carcinoma in situ: possible utility in planning sentinel lymph node biopsy
Utility of internal mammary lymph node biopsy in breast cancer
Long term follow up after 664 sentinel node biopsies: local axillary failure and overall survival
Patterns of cellular distribution within the sentinel node positive for breast cancer
Gene expression by standardized quantitative RT-PCR in the special histologic subtypes of estrogen receptor positive invasive breast cancer
One-step nucleic acid amplification for intra-operative detection of lymph node metastases in breast cancer patients
Discrepancy between triple negative phenotype and basal-like tumor: an immunohistochemical analysis based on 150 "triple-negative" breast cancers
Prophylactic mastectomy - trends in pathology findings
Multiplexed immunohistochemical quantitative molecular phenotyping via multispectral imaging and automated segmentation
Assessment of ErbB2 gene amplification with quantitative real time PCR
Scoring system to predict malignancy in patients diagnosed as atypical ductal or lobular hyperplasia on ultrasound-guided core needle biopsy
Identification of commonly aberrant genomic regions using high-resolution array CGH on paraffin-embedded breast cancer samples
Correlation between breast core biopsies of uncertain malignant potential and subsequent excision biopsies
Fine needle aspiration cytology material is highly suitable for mRNA extraction and subsequent molecular analysis of breast cancer
The borderline amplified HER2 FISH result on breast core biopsy: indications for further sampling do affect patient management
Core biopsy following neoadjuvant chemotherapy in breast cancer - a tool to predict both residual disease and plan axillary treatment
Medico-economic evaluation of the rapid diagnosis of breast lesions using fine-needle aspiration in a one stop breast clinic
Equivocal triple assessment summary scores - do they mean anything?
Is diathermy excision of gynaecomastia superior to saline adrenaline and sharp dissection technique?
The accuracy of preoperative core biopsy in patients with ductal carcinoma in situ
Breast biopsy for mammographically detected nonpalpable lesions using a vacuum-assisted biopsy device (Mammotome) and an upright-type stereotactic mammography unit
Racial differences in frequency and spectrum of BRCA1/2 mutations in young women with breast cancer
A transcription factor-centric computational analysis of genes differentially expressed in healthy breast tissues from African American and Caucasian women
Identification of protein expression differences in invasive breast tumors from African American compared to Caucasian women
NCIC CTG MAP.3: enrollment and study drug adherence of ethnic minority women in a breast cancer prevention trial
Ethnicity and breast cancer: risk and predictors in a prepaid health plan
Identification of trends in large breast cancers in an ethnically diverse population
Patterns of therapy and adherence to established treatment guidelines in caucasian versus African-American new-episode breast cancer patients
Multiethnic comparisons of genome-wide alterations in breast cancer using paraffin embedded samples
A prospective study comparing clinical rheumatological findings and tenosynovial and synovial changes on magnetic resonance imaging of breast cancer patients receiving adjuvant aromatase inhibitors or tamoxifen
A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment
How compliant are patients with oral hormonal therapies? Data from a randomized, placebo controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (NCIC CTG MA.12)
Multicenter phase II randomized trial evaluating toxicities of concurrent and sequential radiotherapy and letrozole (COHORT) as adjuvant therapy after conservative surgery in postmenopausal women with hormone receptor positive tumors: preliminary results
Distant metastasis: the most common type of early recurrence with adjuvant tamoxifen therapy
Acceptance of extended hormonal therapy with letrozole after 5 years of adjuvant tamoxifen in post menopausal breast cancer patients in Calgary, Alberta
Chronological changes of side effect profile of anastrozole compared with tamoxifen in Japanese women: findings from N-SAS BC03 trial every 3 months after one year of the randomization
First results of the prospective Hospital del Mar Bone Health Breast Cancer study (HMBHBC) in postmenopausal women receiving adjuvant aromatase inhibitors for early breast cancer
Compliance with tamoxifen and arimidex in the adjuvant treatment of women with breast cancer
Risk of contralateral breast cancer in patients receiving adjuvant aromatase inhibitor - the rate of positive biopsies for cancer
Phase II feasibility trial incorporating bevacizumab into dose dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial of the Eastern Cooperative Oncology Group (E2104)
BCIRG 006: quality of life (QoL) of patients (pts) treated with docetaxel and trastuzumab-based regimens in node positive and high risk node negative HER2 positive early breast cancer
Cardiac safety of adjuvant bevacizumab plus dose-dense doxorubicin/cyclophosphamide followed by nanoparticle albumin-bound paclitaxel in patients with early stage breast cancer
Preliminary results of a multicenter study of bevacizumab with 3 docetaxel-based adjuvant breast cancer regimens
Pre-anthracycline and herceptin cardiac scanning for adjuvant breast carcinoma: a retrospective analysis of results in Scotland's biggest cancer centre
Adjuvant trastuzumab uptake outside of clinical trials
Final toxicity analysis of the ADEBAR phase III study evaluating the role of docetaxel in the adjuvant therapy of breast cancer patients with extensive lymph node involvement
T1N0 triple negative breast cancer: adjuvant chemotherapy treatment and risk of recurrence
The incidence of thromboembolism in patients receiving adjuvant anthracycline based chemotherapy for early stage breast cancer
Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose-dense FEC and docetaxel - results of a randomized, open-label phase II study
A feasibility study of capecitabine monotherapy for elderly patients with high risk early breast cancer
Delivery of adjuvant dose dense doxorubicin+cyclophosp hamide→paclitaxel to early stage breast cancer patients with pegfilgrastim and darbepoetin alfa support - interim results from an Australian phase II study
A pilot study to investigate the feasibility and cardiac effects of pegylated liposomal doxorubicin (PL-DOX) as adjuvant therapy in elderly breast cancer patients
Adjuvant chemotherapy in breast cancer patients older than 70 years
Annual hazard rates of recurrence for early breast cancer. What has changed in the last 10 years? Results from the NORA study
Do patients with infiltrating lobular carcinoma (ILC) have an increased risk of contralateral, local, or distant recurrences compared with patients with infiltrating ductal carcinoma (IDC)?
Prognostic effect of amenorrhea and return of menses after adjuvant treatment of premenopausal patients with node-positive breast cancer
Detection of minimal residual disease (MRD) in peripheral blood of primary breast cancer patients - translational research in the SUCCESS-study
Biological risk assessment based on snap frozen tissue samples. Feasibility, qualitiy assuance and study progress of the multicenter trial NNBC 3-Europe
Evaluation of practice patterns in the treatment of node-negative, hormone-receptor positive breast cancer patients with the use of the oncotype DX assay at the University of Pennsylvania
Reduced use of HRT by women in Victoria Australia in 2002 was not followed by a fall in breast cancer incidence
Withdrawn by author
The effects of vaginal estrogens on plasma estradiol levels in women taking aromatase inhibitors
Use of hormonal therapies before and after diagnosis of a high risk breast lesion among 1,198 women in the community setting
The multidisciplinary management of menopause symptoms after breast cancer
Protein kinase C-epsilon and -eta confers TRAIL resistance in breast cancer cells via distinct mechanisms
Naphthaquinones - Promising anticancer agents against breast and ovarian cancers
Contribution of chromosomal alterations to the development of poorly-differentiated invasive breast carcinomas
Mouse mammary tumor virus-related sequence expression in the patients with breast phyllodes tumors
Interactions between breast cancer cells and their their stromal component: an analysis of alterations in gene expression
Insulin sensitivity gene expression and efficacy of systemic adjuvant therapy in women with early breast cancer
Targeting up-regulated notch signaling in the CD133+ stem cells within the protected niche of the lymphovascular embolus of inflammatory breast cancer
The overexpression of ERBB receptor tyrosine kinases and ABC transporters is associated with an increased side population in hormone resistant breast cancer cells
CTEN and LKB1: novel tumor biomarkers for breast cancer implications of resistance and response to tyrosine kinase inhibitor (TKI)-based therapies in breast cancer
HER2 increases the translational rates of acetyl-CoA carboxylase alpha and fatty acid synthase in breast cancer cells
The identification of proteins associated with radiotherapy resistance in breast cancer cells: screening 725 antibodies simultaneously using novel microarray technology
A combined proteomic and microarray screening approach for the identification of proteins associated with radiotherapy resistance in breast cancer cells
Genomic signature of invasive lobular cancer by DNA array hybridization
The genomic relationship between breast carcinomas and their paired lymph node metastases
A Q-RT PCR profile for the cytological diagnosis of early breast lesions
Breast cancer classication according to "stem cell-like" features and its relevance for systemic adjuvant treatment decision
DNA hypermethylation profile of inflammatory breast cancer
Changes of stromal protein expression after preoperative systemic therapy in breast cancer
Vitronectin in the tumor microenvironment promotes breast cancer cell proliferation and elevated protein synthesis despite hypoxia by integrin αvβ3 activation of the mTOR/4E-BP1 pathway
Caveolin-1 enhances the growth inhibitory effects of gefitinib in MCF-7 breast cancer cell line
The downregulation of cyclin B1 sensitizes the antiproliferative effect of chemotherapeutics in breast cancer cells
ER dependent regulation of sphingolipid metabolism in the context of apoptosis and proliferation in breast cancer
Studies on the role of nicotinic receptors-mediated cell proliferative effects in human breast cancer cells
Osteocalcin as a prognostic indicator in ductal mammary carcinoma
Expression and activity of core binding factor (CBF) in human breast cancer cells
Immunohistochemical expression of YKL-40 is not a prognostic marker in patients with high-risk primary breast cancer
Early changes in expression of oestrogen-regulated and proliferation genes illustrate heterogeneity in primary resistance to letrozole
Radiation-induced CD8 T-lymphocyte apoptosis yield predicts toxicities after adjuvant treatment with concurrent and sequential radiotherapy and letrozole in postmenopausal women with hormone receptor positive breast cancers: preliminary results of the multicenter phase II randomized trial (COHORT)
Signal pathway profiling of primary breast tumors identifies potential phosphoprotein biomarkers that are predictive for tamoxifen response following recurrence
Selective serotonin reuptake inhibitors and modification of tamoxifen effectiveness in Danish breast cancer patients
Predictive gene expression profile of breast cancer patients treated with tamoxifen
Biomarker analysis of a phase II double-blind randomized trial of daily oral RAD001 (everolimus) plus letrozole or placebo plus letrozole as neoadjuvant therapy for patients with estrogen receptor positive breast cancer
Risk categorisation of node positive tamoxifen treated breast cancer patients based on genetically defined subtypes
ABCB1 MDR1) inherited polymorphisms in relation to doxorubicin and docetaxel pharmacokinetics in patients with breast cancer
Breast cancer proteomic profiles of tumor susceptibility to neoadjuvant chemotherapy
47% pathologic complete response rate to anthracyclines-based associated with high cyclophosphamide doses neoadjuvant chemotherapy in basal-like and triple negative breast cancer patients
Pharmacogenetic influences on outcome from AC chemotherapy in the treatment of breast cancer
COX-2 over-expression and sensitivity to celecoxib and capecitabine in metastatic breast cancer patients
Thymidine phosphorylase expression is associated with time to progression in patients receiving docetaxel-modulated capecitabine for metastatic breast cancer
The presence of the FRA12E/SMRT fragile site in the genome of breast cancer (BC) patients is a predictor of metastatic development
Correlation of IGF1R gene expression and mutations with the risk of local recurrence in early breast carcinoma treated with conservative surgery and radiation therapy
A retrospective clinical correlation study of the breast cancer patients' responses to anticancer drugs with the expression level of drug response indicators (DRI) measured in patient's archival tumor tissue
Estrogen receptor status: a prognostic predictor of outcome in HER-2 positive breast cancer with brain metastases
The potential prognostic value of osteoprotegrin in ductal carcinoma of the breast
The initial response of circulating epithelial tumor cells to primary systemic chemotherapy in breast cancer is highly predictive for final tumor reduction and outcome
Predictors of response to neoadjuvant chemotherapy in women with locally advanced breast cancer
Prognostic determinants in patients with breast cancer who are staged using sentinel lymph node biopsy
Significance of Akt activation and compartmentalization for prediction of outcome in Her-2 positive breast cancer patients treated with trastuzumab
Use of flow cytometry to identify breast cancer patients likely to benefit from specific targeted therapies
Is pathologic complete response related to level of hormonal receptor positivity in hormonal-sensitive breast cancer treated with anthracycline-based neo-adjuvant chemotherapy?
Serum markers predictive of chemotherapy-induced premature ovarian failure among premenopausal women with early stage breast cancer
Women with elevated body mass index at increased risk of breast cancer with a poor prognosis
Risk factors for developing breast cancer following benign breast disease: a 25-year follow-up of a nationwide cohort
Withdrawn by author
Traditional breast cancer risk factors and common breast pathologies in post-menopausal women
Validation of the Gail model for breast cancer risk in postmenopausal women with osteoporosis
A pilot study of known or controversial breast cancer risk factors using the Clinical Breast Care Project database as a research environment
Absolute breast fibroglandular volume strongly associated with breast cancer risk
Large errors in volumetric fibroglandular density occur if breast thickness and paddle tilt are not measured
The ratio of the estradiol metabolites 2-hydroxyestrone (2OHE1) and 16a-hydroxyestrone (16aOHE1) predicts breast cancer risk in postmenopausal but not in premenopausal women - a case-control study
Type II diabetes and breast cancer; a potentially modifiable risk factor?
Reproductive risk factors and breast tumor characteristics in African American and non-Hispanic White women with early onset breast cancer
Sub epithelial impedance: a new biomarker of breast cancer risk
The OncoVue® model for predicting breast cancer risk
A study of relationship between lipophilic statin use and estrogen receptor negative breast cancers
Phase II tissue-based biomarker prevention trial of celecoxib in premenopausal women at high risk for development of breast cancer
Immunomodulatory effects of celecoxib in patients at increased risk for breast cancer
Cumulative effects of raloxifene on the incidence of breast cancer over 8 years in postmenopausal women with osteoporosis
Incidence of breast cancer in postmenopausal women after discontinuation of long-term raloxifene use
Relative cost-effectiveness of raloxifene and tamoxifen in chemo-prevention of breast cancer with less thrombo-embolic events than no chemoprevention
Tamoxifen for the prevention of breast cancer development: an updated meta-analysis
Prevention of breast cancer using rexinoids: results of a phase II biomarker modulation trial using bexarotene in women at high risk of breast cancer
Chemoprevention in a mouse model for ductal carcinoma in situ: targeting the mTOR pathway
A strong association between body fat mass and proteomes of nipple aspirate fluids
Prophylactic mastectomy: pathological findings in high risk women
A pilot study to increase physical activity in sedentary women at risk for breast cancer
Improving informed consent in clinical trials: a randomised controlled trial of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II)
Effect of green tea extract and tamoxifen on mammary carcinogenesis of C3H/OuJ mouse
Lyophilized aqueous extract of American ginseng (AG) abrogates induced COX-2 expression in human breast cancer cells
Conjugated linoleic acid synergizes with the CYP1B1 inhibitor 2,3′,4,5′-tetramethoxystilbene in suppressing breast cancer cell growth
Serving the high risk patient in community practice: development and managment of a high risk clinic
Trastuzumab treatment beyond progression in patients with HER-2 positive metastatic breast cancer - the TBP study (GBG 26/BIG 3-05)
Retrospective evaluation of clinical outcomes in HER2-positive advanced breast cancer patients progressing on trastuzumab-based therapy in the pre-lapatinib era
Evaluation of first-line trastuzumab in combination with epirubicin/cyclophosphamide for patients with HER2-positive metastatic breast cancer
Clinical use of trastuzumab (Herceptin®) in metastatic breast cancer (MBC) in Germany from 2001 to 2006
HER-2 positive inflammatory breast cancer: high pathological response rate with trastuzumab-based neoadjuvant therapy
Survival gain by trastuzumab therapy after the onset of intracranial metastasis in metastatic breast cancer
A phase II trial of docetaxel with bevacizumab as first line therapy for Her2/neu negative metastatic breast carcinoma
Bevacizumab combined with chemo-endocrine preoperative therapy in locally advanced operable breast cancers
Capecitabine + docetaxel + bevacizumab as neoadjuvant therapy for invasive breast cancer: results of a phase II pilot study
Increased use of breast-conserving surgery: preferred treatment or failure to provide adequate local therapy?
Impact of the interval between breast conserving surgery and adjuvant radiotherapy on clinical outcomes in early stage breast cancer
Breast-conserving therapy: balancing surgery and radiation
Cosmetic effect of breast radiotherapy in older women
Breast conservative therapy results of triple negative breast cancer
Does surgical closure technique affect early mammographic detection of tumor recurrence following breast-conserving therapy?
Stem cell augmented reconstruction: a new hope for reconstruction after breast conservation therapy
Co-transplantation of adipose tissue-derived regenerative cells improves long-term retention of fat graft
Radiofrequency ablation therapy for breast cancer
Concurrent chemoradiation with capecitabine achieves meritable response and local control for inoperable and recurrent neoadjuvant chemotherapy refractory breast cancer
The late radiotherapy normal tissue phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependant causes
Increased use of regional radiotherapy is associated with improved outcome in a population-based cohort of women with breast cancer and 1-3 positive nodes
Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer
Toxicity and cosmesis from RTOG 95-17: a phase I/II trial to evaluate brachytherapy as the sole method of radiation therapy for stage I and II breast carcinoma
Update of the phase II MammoSite® brachytherapy trial for DCIS
Partial breast irradiation using the MammoSite® device for low risk breast carcinoma in patients aged ≥ 60 years: toxicity, cosmesis and quality of life results of a phase II study
Intra-fraction motion during tangential treatment of the left breast: how consistently is the heart actually blocked?
Prospective trial of individual optimal positioning (prone versus supine) for whole breast radiotherapy: results of 194 patients
Relative importance of posterior and upper borders of tangential radiation portals in axillary lymph node coverage after breast conserving surgery
Post-operative radiotherapy does not adversely affect the outcome of autologous free abdominal flap breast reconstruction
Linear accelerator-based intraoperative radiotherapy in limited stage breast cancer - results of an ISIORT pooled analysis in 1131 patients
The Cambridge breast intensity modulated radiotherapy trial: dosimetry results for 1089 patients
Utilization of fiducial markers in accelerated partial breast irradiation with intensity modulated radiotherapy (IMRT)
Intervals longer than 20 weeks from breast conserving surgery to radiation therapy are associated with inferior outcome for women with early stage breast cancer not receiving chemotherapy
Are patients with T1-2 breast cancer with 1-3 positive nodes suitable candidates for partial breast radiotherapy trial enrolment?
Lumpectomy and accelerated partial breast irradiation as an alternative to mastectomy following prior mantle field radiation or breast irradiation
Surgeon characteristics and receipt of adjuvant radiotherapy following breast conservation surgery in elderly women with breast cancer
Non-invasive imaging techniques quantify radiation induced vascular changes in the breast
The identification of patients for postmastectomy radiotherapy using the Cambridge index: audit of a prospective series
Postmastectomy locoregional recurrence in Hong Kong: low risk patients without radiotherapy have more failures than intermediate risk patients with radiotherapy
Thyroid dysfunction following modern three-dimensional conformal radiation therapy to low neck in women with breast cancer - a dosimetric, volumetric, and biochemical assessment
Oesophageal carcinoma as second malignancy after irradiation for breast cancer. From meta-analysis and large epidemiological studies to patients' records and dosimetric questions: where is the truth? Large scale single institutional experience
Patient rated breast symptoms and body image in early breast cancer: first results of the UK standardisation of breast radiotherapy (START) trials
Distinct cancer stem cells may mediate heterogeneity among the human breast premalignant lesions
Preliminary characterization and in vitro propagation of putative stem/progenitor cells from human inflammatory breast cancer
Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and proliferation through MMP-dependant and -independant mechanisms
Distinct chemokines mediate tumourigenicity of breast cancer cells
BRCA1 transcriptionally regulates the genes associated with the basal phenotype in breast cancer
Development of in vitro models to study microenvironmental influences on breast cancer progression
MCF7 and MDA-MB-231 cells cultured on Poly-HEMA-coated dish are more invasive, yet show less tumourigenicity, than cells cultured on the tissue culture dish
The anti-aromatase effect of the natural metabolites of progesterone: 20α-dihydroprogesterone and 5α dihydroprogesterone in MCF-7aro breast cancer cells
Development of resistance to targeted therapy strategies transforms the clinically-defined molecular profile subtype of breast tumors
The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell-cycle progression in-vitro and in-vivo
Profiling HER-family receptor dimerization in HER2 overexpressing cells that coexpress mutated EGFR receptors
ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen resistant MCF-7 cells leading to the activation of AKT and p90RSK
Reverse phase protein array analysis of an ER-positive/HER2-positive breast cancer xenograft model reveals distinct resistance mechanisms to HER2 targeted therapy
Carcinoembryonic antigen cell adhesion molecule 6 has a functional role in endocrine resistance
The role of amphiregulin in exemestane-resistant breast cancer cells: evidence of an autocrine loop
α6β1 and α6β4 integrins and their critical role in promoting resistance to multiple treatment strategies for breast cancer
Kinome survey of molecular pathways lead to tamoxifen-resistant breast cancer cell growth
On the role of calpain in regulation of HER2 and resistance to trastuzumab in breast cancer cells
P450 aromatase regulation by autocrine human growth hormone confers resistance to aromatase inhibitors in a human mammary carcinoma cell line
Tissue inhibitor of metalloproteinases-1 influences sensitivity to etoposide in MCF-7 S1 breast cancer cells
Molecular etiology of breast cancer: potential biomarkers of risk and for use in prevention
Increased detection of breast cancer markers human epidermal growth factor receptor dimer and downstream signaling proteins utilizing the VeraTag technology with dextran modified antibodies
Changing pattern of the detection of loco-regional relapse in breast cancer: the Edinburgh experience
Value of clinical follow-up following breast conserving treatment for breast cancer
Estrogen plus progestin and breast cancer detection with mammography and breast biopsy
Galactose oxidase Schiff's reactivity is higher in nipple aspirate fluid from cancerous breasts than from healthy patients
Hormonal attributes of breast ductal lavage fluid in pre- and post-menopausal women. Effect of tamoxifen
Novel impedance device to detect breast cancer in younger women
Intraoperative in vivo reflectance spectroscopy for discrimination of normal, benign, and malignant breast tissues
Water state changes in malignant and benign breast tumors measured by diffuse optical spectroscopy in vivo
Sonopheresis and ductal epithelial impedance spectroscopy as a non-invasive technique for breast cancer diagnosis
Combination of mammogram BI-RADS data and serum mass spectrometry proteomic profiles in improving breast cancer diagnosis
Identification of a metabolic fingerprinting for metastatic breast cancer by proton nuclear magnetic resonance spectroscopy-metabolomic analysis
Identification of blood-based biomarkers for the detection of breast cancer and lymph node status
Moved to Poster Session VI
Discovery of serum biomarkers for breast cancer detection
Protein markers for the stratification of breast cancer patients
Detection of oligometastases in breast cancer by using tumor markers
Serum HER2 compared with CA153 for the monitoring of advanced breast cancer
Liquid FISH-like assay for detection of HER-2 gene amplification in the serum of patients with breast cancer
CA 15-3 level at time of metastatic relapse of breast cancer strongly correlates with hormone receptor but not with Her2 expression
Differential gene expression in circulating tumor cells between primary and metastatic breast cancer patients
Metastasis in blood of breast cancer patients
RASSF1ADNA methylation in bone marrow (mRASSF1ABM) or peripheral blood plasma (mRASSF1APB) of primary breast cancer (BC) patients
Incidence and kinetics of circulating tumor cells in breast cancer patients treated with primary systemic therapy including trastuzumab for patients with HER2-positive tumors - a translational project within the study "GeparQuattro"
Web calculators for estimating the risk of breast cancer death and the impact of adjuvant treatment on that risk
Nodal ratios as an alternative to pN-staging in node-positive breast cancer: a validation study
Automated image analysis for high-throughput quantitative detection of ER and PgR expression levels in large-scale clinical studies: the TEAM trial experience
Estrogen receptor and breast cancer survival in a Kaiser permanente population-based study: comparison of quantitative reverse transcriptase polymerase chain reaction and immunohistochemistry
Androgen receptor determination in breast cancer: a comparison of the dextran-coated charcoal method and quantitative immunohistochemical analysis
Human epidermal growth factor receptor 2 (Her-2/Neu), immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) testing at McGill University Health Centre: a comparison of absolute FISH copies (FISH-ABS abs) with Her-2 COPY/chromosome 17 ratio (FISH-17 RATIO) in 198 consecutive early breast cancer cases
Quality control procedures are essential in accurate HER2 FISH testing using automated morphometric image analysis
Impact of ERBB2 on prognosis and microarray data
Reproducibility of HER2-analysis in a national survey performed at 24 routine pathology departments in Sweden
Assessing HER-2 status via virtual microscopy
Intrinsic near-infrared spectroscopic biomarkers applied for evaluation of final pathological response to neaoadjuvant chemotherapy
Prognosis-prediction model using multimarker in lymph node negative breast cancer by decision tree analysis
Bayesian analysis of recurrence in lymph node positive and lymph node negative breast cancer patients
Stage migration of breast cancer using two techniques of tumor size assessment and its impact on projection for survival and treatment decision making
Withdrawn by author
Sentinel node biopsy in ductal carcinoma in situ of breast - a meta-analysis
Pathologic and radiographic response of ER-positive DCIS to neoadjuvant letrozole therapy
ERISAC trial: evidence exemestane effects oestrogen receptor (ER) positive ductal carcinoma in situ (DCIS) proliferation
Genetic and phenotypic characteristics in pleomorphic lobular carcinoma in situ
Molecular profiling of DCIS: identification of distinct subgroups of potential prognostic importance
Suboptimal local control of ductal carcinoma in situ of the breast is associated with inferior 10-year breast cancer specific survival in a population-based cohort of women treated with breast conserving surgery
Can subcutaneous mastectomy be considered an alternative for ductal carcinoma in situ treatment, when breast conservation is not possible?
Male breast cancer (MBC): impact of early diagnosis and adjuvant treatments. Analysis of 983 cases
Survivin and COX-2 expression in male breast cancer
Patterns of body size in male breast cancer and impact of obesity on disease outcome
Expression of basal-like markers in male breast cancers
Significant improvement in disease free and overall survival with neoadjuvant, dose intensified two weekly treatment with anthracycline and taxane in primary breast cancer, including inflammatory disease. Fifty five months median follow up results of a multicenter prospective randomised phase III AGO-trial
Evaluating the efficacy and safety of trastuzumab given concomitantly to epirubicin/cyclophosphamide → docetaxel±capecitabine as neoadjuvant treatment of HER2 overexpressing primary breast cancer. First analysis of the GBG/AGO intergroup-study "GeparQuattro"
Development of a genomic tool to predict pathologic complete remission in a community-based, preoperative, phase II trial of 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel-capecitabine for stage II, III breast cancer
Primary systemic therapy using docetaxel/cyclophosphamide/bevacizumab (TCB) followed by doxorubicin (A) in operable or locally advanced breast cancer (BC)
Randomized placebo-controlled phase 11 trial with preoperative epirubicin and cyclophosphamide +/− gefitinib in patients with operable and estrogen receptor negative breast cancer
Efficacy and safety results from a randomized, phase II trial of neoadjuvant capecitabine + epirubicin + cyclophosphamide vs 5-FU + epirubicin + cyclophosphamide in operable breast cancer
Sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients: results of the planned interim analysis and analysis of predictive parameters. Supported by PHRC AOM/2002/02117, Pfizer inc., Roche, sanofi-aventis
Neoadjuvant capecitabine plus docetaxel ± trastuzumab therapy for recently diagnosed breast cancer: phase II results
Dose-dense docetaxel, carboplatinum and trastuzumab as neoadjuvant therapy for human epidermal growth factor receptor-2 - positive stage II and III breast cancer
High pathologic complete response rate effectively predicted by proliferation index in HER2-positive localized breast cancer tretated with weekly paclitaxel followed by FEC with concurrent trastuzumab
The influence of T-cells on the response to a neodjuvant therapy with do-cetaxel/epirubicin/cyclophosphamide (TEC)
Preliminary recurrence and survival analysis of patients (pts) receiving neoadjuvant q4week carboplatin and weekly paclitaxel ± weekly trastuzumab in resectable and locally advanced breast cancer: update of BrUOG BR-95
Pharmacokinetic and pharmacodynamic analysis of cyclophosphamide, epirubicin and capecitabine vs 5-FU, epirubicin and cyclophosphamide as neoadjuvant therapy in breast cancer patients
Does combination of neoadjuvant and adjuvant chemotherapy improve outcome in operable breast cancer patients?
Pathologic complete response following paclitaxel (cremophor or albumin bound) + carboplatin ± trastuzumab ± bevacizumab sequenced after in vivo chemosensitivity-adapted dose-dense doxorubicin-cyclophophamide in inflammatory breast cancer
Epirubicin and docetaxel as neoadjuvant treatment of locally advanced breast cancer: a phase II study
Neoadjuvant biweekly chemotherapy with liposomal doxorubicin and docetaxel in patients with stage II-III breast cancer
Phase II study of a 3-weekly liposome-encapsulated doxorubicin/docetaxel/pegfilgrastrim in combination with weekly trastuzumab as primary treatment in HER2 positive (HER2+) early stage breast cancer patients (II-IIIa). Intermediate analysis of 26 patients. GEICAM 2003-03 study
Aphase IV study of neo-adjuvant combination chemotherapy with pegylated liposomal doxorubicin (CAELYX®) and vinorelbine for locally advanced breast cancer
The farnesyl transferase (FT ase) inhibitor (FTI) tipifarnib inhibits FT ase in vivo and enhances the efficacy of neoadjuvant dose-dense doxorubicin-cyclophosphamide (AC) in patients with locally advanced breast cancer (LABC)
A phase 2 trial of neoadjuvant letrozole for postmenopausal patients with stage 2 and 3 ER and/or PgR+ breast cancer - endpoint comparisons
A randomized phase II neoadjuvant trial in patients with stage II-III and inflammatory breast cancer
Clinical relevance of neoadjuvant chemotherapy in invasive lobular carcinoma of the breast
Tumor and normal interstitial fluid proteomic characterization in breast cancer patients receiving neoadjuvant chemotherapy
Pathological and clinical outcomes in response to neoadjuvant chemotherapy: a comparison of basal-like, hormone receptor-positive and HER2-positive breast cancers
Optimal loco-regional treatment of the primary tumor in metastatic breast cancer patients is associated with a significant survival advantage
NEW START: the United Kingdom sentinel lymph biopsy training programme. A model of how multi-professional training can achieve competent national performance whilst maintaining patient safety
The effect of dedicated breast surgeons on the short term outcomes in breast cancer
Shared decision-making in routine clinical practice: the example of breast cancer in a regional cancer centre in France
Paget's disease of the nipple in a population based cohort
Infiltration of ropivacaine efficacy on acute breast pain after surgery for breast cancer. Preliminary results of a multicentric study
Surgical follow up and clinical presentation of 142 of breast papillary lesions diagnosed by ultrasound guided breast biopsy
Oncologic safety of nipple areola complex preservation for breast cancer; 5 year follow-up result
Breast surgery for women presenting with stage IV breast cancer
Can the resection of primary breast cancer improve survival of patients with stage IV breast cancer?
Cosmetic outcome after latissimus dorsi based breast reconstruction: comparing the effects of radiotherapy and time
Interval inset of TRAM flaps in immediate breast reconstruction: a technical refinement
Immediate two-stage breast reconstruction and irradiation with a tissue expander and an implant: results, risk factors for failure and self-evaluation
Skin-sparing mastectomy and immediate 'mini-flap' reconstruction - a novel technique
Staged sentinel node biopsy to guide timing of breast reconstruction
Rib fractures: a complication of radiation therapy and tissue expansion for breast reconstruction
Does quality of life after breast reconstruction change with time?
Three-dimensional imaging provides valuable clinical data to aid in unilateral tissue expander-implant breast reconstruction
Postoperative analgesia and flap perfusion after pedicled TRAM flap reconstruction - continuous wound instillation with ropivacaine 0.2% - a pilot study
Optimizing surgical technique for total skin-sparing mastectomy
Quality of life and morbidity at medium term follow up after sentinel lymph node, and immediate or delayed axillary disssection
Radiation after axillary lymph node dissection: impact of neoadjuvant chemotherapy
Intraoperative ultrasound localization of nonpalpable breast cancers
Tumor stage of the primary breast cancer is a predictor of the size of local recurrence
Minimally invasive excision of gynaecomastia - a novel and effective surgical technique
Evidences that progesterone receptor b decreases estrogen receptor gene expression through its interaction to a half-PRE site at estrogen receptor gene promoter
Influence of estrogen receptor expression on HER2 mRNA levels in HER2-gene amplified breast cancer tumors as measured using FISH and the novel DASL assay
Detection of elevated HER2/neu levels in breast cancer cell lines overexpressing estrogen receptor β
Mammary fibroblasts express ERβ1 and ERβ2 and can modulate breast cancer behaviour in a co-culture model
Expression of estrogen receptors β in triple negative breast cancer
Immunohistochemical expression of CK5/6, CK17, ERβ in triple negative breast cancer patients
High phosphorylation of estrogen receptor α serine 167 and low p53 protein accumulation improve survival in estrogen receptor-positive breast cancer patients treated with tamoxifen
Characterization of estrogen receptor positive breast cancers: gene expression analysis of archived tumours
Identification of gene expression differences in primary breast tumors from node-negative and node-positive women
Identification of a gene expression breast cancer metastasis profile
Genomic discrimination of metastatic from non-metastatic primary breast tumors
Tumor microenvironment in breast cancer metastasis: direct tissue protein profiling of tumor-associated stroma from invasive breast cancer patients with versus without axillary lymph node metastasis
Biomarker analyses in Japanese refractory advanced breast cancer patients treated with lapatinib monotherapy
EGFR, pAkt and pPI-3 kinase are co-expressed in circulating tumor cells of breast cancer patients
CD146-downstream signaling mediating breast tumour invasion/metastasis
Xenograft model for the evaluation of breast cancer metastatic progression
Rhodiola crenulata decreases invasion and regulates cyclooxygenase-2 expression in a highly metastatic ER-negative breast cancer cell line
Lymphangiogenesis in breast cancer: correlation with lymphatic microvessel density and clinicopathologic parameters
Loss of nuclear p27 is independently associated with young age at breast cancer diagnosis
Stratifying primary operable breast cancers by steroid and HER-2 expression status predicts short term disease free survival
Comparison of prognostic value of hormonal receptors (HR) and HER-2 overexpression on overall survival (OS) in breast cancer
Correlation of ER/PR status and HER-2 status in invasive breast carcinoma
Prognostic significance of HER2 status in women with inflammatory breast cancer
Validation of an immunohistochemical biomarker for identifying Her2+ patients at high risk of recurrence
Prognostic value of both HER-2 and VEGF-A mRNA overexpression in primary tumors of high-risk breast cancer patients
The pathological characteristics of gestational breast cancer. What is different?
The mitotic activity index is able to separate two prognostic subgroups in grade II estrogen receptor (ER)-positive node-negative breast carcinomas
Assessing final pathological response to neoadjuvant chemotherapy using diffuse optical spectroscopy
The ProEx Br immunohistochemical assay has prognostic utility in early stage breast cancer using a manual scoring method
CXCR4 coexpression with EGFR/HER2 positivity in breast cancer is a poor prognostic factor in patients with isolated tumor cells in bone marrow
Characterization of a good prognosis set of genes in breast cancer patients with at least 5 involved lymph nodes
Cytogenetic heterogeneity within breast tumor specimens is revealed by the eXagenBC test
An alternatively spliced variant of cyclin D1 is present in human breast carcinoma
Evaluation of prognostic factors influencing the therapeutic management of post-treatment metastatic breast cancer. A retrospective study on 1096 patients who have been treated between 1980 to 2005 at the Centre Antoine Lacassagne
Brain metastases in HER2+ metastatic breast cancer patients: analysis of prognostic factors
Clinical outcome of patients with triple negative (TN) breast cancer who develop brain metastasis
Characteristics of breast cancer patients with central nervous system metastases and factors associated with survival after development of central nervous system metastasis
Brain metastases in breast cancer: a retrospective cohort study of 187 patients and prognostic markers determination
Withdrawn by author
Topoisomerase 2 α gene amplification and protein expression in fresh and recurrent breast cancers
Cyclin-dependent kinase 1 and 2 activity as prognostic markers in early breast cancer
Prognosis and clinical outcome of patients with node negative ≤ 1 cm breast cancer
MAPK expression is associated with poor outcome in patients with hormone receptor negative breast cancer
The role of the stromal immune response in breast cancer recurrence
Comparison of patients with "triple negative" breast cancer (ER−, PR−, HER2−) in a cohort of 1052 patients treated in a single institution between 1999 and 2007
Obesity at diagnosis increases relapse rate and shortens disease free interval in breast cancer patients
Elevated MIB-1(%) and c-myc amplification are relevant prognosticators of ER positive/HER2 negative ("luminal A") primary breast cancers
Allelic imbalance and predictors of outcome in ipsilateral breast tumor recurrences after systemic therapy for early stage breast cancer
Impact of progesterone receptor (PR) status on survival of estrogen receptor (ER) positive women with invasive breast cancer (IBC)
Tumor biology of breast carcinoma in elderly women: comparison between elderly and young postmenopausal women
A community-based single institution registry study of treatment outcomes in breast cancer patients with 4 or more positive lymph nodes
HMGA2 with uPAI/PAI-1 as prognostic factors in node negative breast cancer patients
Defining endpoints for recurrence in randomized controlled trials of systemic therapy for early breast cancer: a call for standardization
Has the quality of early breast cancer randomized controlled trials publications improved since CONSORT? A systematic review
Moving from informed consent to informed choice: an ethical imperative from regional pilot to nation-wide clinical trial matching service
Inflammatory breast cancer biorepository: research collaboration
Community-based outreach is an effective strategy for linking underserved women to breast cancer screening: data from the Avon Foundation Breast Care Fund
Improving access to care in an AVON Foundation Comprehensive Breast Center (AFCBC) serving a predominantly urban African American (AA) patient population
A comprehensive diagnostic program for medically underserved women with abnormal breast screening evaluations in an urban population
Enhancing communication between oncologists and breast cancer patients
Upfront: new perspectives on breast cancer - report by the Canadian Breast Cancer Foundation-Ontario Chapter (CBCF-OC)
Counselling women with breast cancer - whose line is it anyway?
Identification and prioritization of unmet medical, educational and psychosocial needs in patients with metastatic breast cancer: results of a patient survey
A family history of breast or ovarian cancer further increases the risk of secondary leukemia, especially chronic leukemia, in breast cancer patients
HER2 status in a US population-based cohort: results from a tissue microarray-based analysis of 2,898 breast cancers from women enrolled in the nurses' health study
registHER: patient characteristics and time course of CNS metastases in patients with HER2-positive metastatic breast cancer
Short-term cancer risk in a cohort of 2,353 women with high-risk breast lesions
Carcinoma and atypical hyperplasia are frequent findings in women with macromastia undergoing reduction mammoplasty: a prospective study
Osteoporosis and breast cancer treatment
Prevalence of anemia in hospitalized French cancer patients: results of a one-day cross-sectional survey
The breast cancer surveillance consortium: a platform for collaborative research stemming from breast cancer risk through survivorship research
Incidence and tumor characteristics of breast cancer diagnosed before and after implementation of a population-based screening-program
The wish for pregnancy after breast cancer, results of a French survey on 269 youngs breast cancer survivors
Survival of breast cancer over the last 30 years in a cohort of 7651 women and up-to-date estimates for patients recently diagnosed
Ethnicity, multiparity and the risk of premenopausal breast cancer. A population-based, multi-ethnic study from Singapore
Time distribution of the recurrence risk for Chinese breast cancer patients undergoing surgery
The rates of chemotherapy-induced amenorrhea in patients treated with different regimen at different ages in Chinese breast cancer paients
HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: preliminary phase 2 results in patients with advanced breast cancer
Preliminary results of a phase 2 study of bosutinib (SKI-606), a dual Src/Abl kinase inhibitor, in patients with advanced breast cancer
mTOR inhibitor nanoparticle albumin-bound (nab) rapamycin is effective in a breast cancer xenograft model
A multicenter phase Ib study of the safety, pharmacokinetics, biological activity and clinical efficacy of INCB7839, a potent and selective inhibitor of ADAM10 and ADAM17
Preclinical characterization of INCB7839, a potent and selective inhibitor of ErbB ligand and HER2 receptor shedding: inhibition of ADAM10 and ADAM17 for the treatment of breast cancer
Tanespimycin (an Hsp90 inhibitor) and trastuzumab is an active combination in patients (pts) with Her2-positive trastuzumab-refractory metastatic breast cancer (MBC): phase 2 trial
Withdrawn by author
CTEP-sponsored phase I/II trial of paclitaxel and low dose suramin in metastatic breast cancer
Combination therapy with the novel epothilone B analog, ixabepilone, plus capecitabine has efficacy in ER/PR/HER2-negative breast cancer resistant to anthracyclines and taxanes
A phase II trial of trastuzumab, weekly ixabepilone (BMS-247550) and carboplatin (TIC) in patients with HER2/neu-positive (HER2+) metastatic breast cancer (MBC): a trial coordinated by the Eastern Cooperative Oncology Group (E2103)
A phase 1 study of ARRY-543, a potent, selective, reversible inhibitor of ErbB receptors
Identification of a small molecule estrogen related receptor α specific antagonist that inhibits cell growth in MCF-7 and T47D breast cancer cells
Exogenous histone H2A induces senescence and differentiation in breast cancer cells
Safety and pharmacokinetics of motesanib diphosphate (AMG 706) with paclitaxel or docetaxel for the treatment of locally recurrent, unresectable or metastatic breast cancer
A prospective study to determine the prevalence of hypovitaminosis D in women with early stage breast cancer treated with an aromatase inhibitor and the benefit of vitamin D supplementation on musculoskeletal symptoms and overall QOL
Lapatinib and capecitabine for the treatment of brain metastases in patients with HER2+ breast cancer - an updated analysis from EGF105084
Lapatinib Expanded Access Program (LEAP): design, operation and initial safety data
A phase I study of sunitinib plus paclitaxel for first-line treatment of advanced breast cancer: preliminary results
Exploratory evaluation of a sequential administration of docetaxel and sunitinib in women with advanced breast cancer
AZD2171 for refractory breast cancer: a phase 2 trial
Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo controlled, randomized phase II study
Preclinical efficacy in breast cancer xenografts and phase 1 results of PTC299, a novel VEGF expression inhibitor
Radiofrequency ablation versus cryoablation of small breast cancer with dedicated probes. Initial clinical experience
Role of differing estrogen receptor status on the proliferative effects of genistein
Maintenance hormonal and immunotherapy in metastatic breast cancer with a clinical benefit from anthracycline-paclitaxel based induction chemotherapy
Efficacy and safety of vaginal testosterone for atrophic vaginitis in breast cancer patients on aromatase inhibitors: a pilot study
Influence of chemotherapy on bone in premenopausal women with breast cancer
The efficacy of sertraline for controlling menopausal symptoms in women with breast cancer
Persistent peripheral neuropathy in breast cancer survivors treated with taxane chemotherapy
Standardized evaluation of regional and institutional breast cancer outcomes
Challenges in metastatic breast cancer: optimistic vs realistic goals for treatment
Differences in care of breast cancer patients in an underinsured population
Second nonbreast malignancies following breast cancer in the Japanese female population
Triple negative, "basal-like" breast cancer: an institutional review
Assessment of efficacy and health related quality of life of proprioceptive neuromuscular facilitation (PNF) arm rehabilitation after surgical treatment of breast carcinoma
The physical therapist's role in minimising impaired shoulder movement after axillary dissection
Management and outcome of elderly patients (70 and over) with early stage breast cancer in rural community setting
High prevalence of vitamin D deficiency or insufficiency in breast cancer patients
Changes in cyclins' and CDKs' mRNA expression during neoadjuvant treatment with letrozole
Differences in recurrent genomic alterations between the molecular subtypes of breast cancer
The corepressor SAFB in breast cancer - identification of target genes
Potential role of dopamine and cAMP-regulated phosphoprotein, Mr 32000 (DARPP-32) in trastuzumab response in breast cancer
Dysregulation of cofactor of BRCA1 expression in breast cancers
Regulation of BRCA1 protein stability and its impact on estrogen biosynthesis in ovarian granulosa cells
A novel anti-Patched1 antibody can suppress hedgehog signaling pathway in human breast carcinoma cells
MicroRNA expression in primary breast tumors
MicroRNAs in triple negative breast cancer
The expression of gene transcripts of telomere-associated genes in human breast cancer: correlation with clinico-pathological parameters and clinical outcome
Expression of the putative breast cancer gene "breast cancer and salivary gland expression"; relationship with microRNA 154* and estrogen receptor status
In vivo imaging of breast cancer using genetically engineered light-emitting bacteria
The four and a half LIM-only protein 2 mediates repression of Plk1 in breast cancer cells
HER-2 gene amplification is a marker for global genomic instability
Array-CGH identifies CCNE1 amplification in ER/HER2 negative breast cancers
Novel Mdm2 intron 1 single nucleotide polymorphisms and their role in breast cancer
HER2/TOP2A amplicon in breast cancer: a microarray-based and chromogenic in situ hybridisation analysis
Genetic polymorphisms in the vascular endothelial growth factor (VEGF) gene and breast cancer risk
Molecular genetics and immunophenotypical characterisation of micropapillary carcinomas of the breast
Impact of deleterious BRCA mutations and unclassified BRCA variants upon breast cancer characteristics at presentation
Premature thelarche variant and estrogen receptor-α coregulator single nucleotide polymorphisms
Heparanase expression in circulating lymphocytes of breast cancer patients is induced by the primary tumor and/or by distant metastasis